Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

Influenza

Phase 2

Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine

CompletedNCT00742885

GlaxoSmithKlineInfluenza

Start: 2008-09-01End: 2009-03-07Updated: 2018-08-20

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

CompletedNCT01416571

GlaxoSmithKlineInfluenza

Start: 2011-08-12End: 2012-09-28Updated: 2018-09-21

Phase 3

Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years

CompletedNCT00616928

GlaxoSmithKlineInfluenza

Start: 2008-01-23End: 2009-03-19Updated: 2018-06-08

Related Papers

Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years.

2014-07-309 citations

Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study.

2011-06-0166 citations

A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults.

2010-11-2510 citations